1. **Date Disclosed:** April 22, 2013  
**Investigator with FCOI:** William Federspiel, Ph.D.  
**Title:** Professor of Chemical Engineering, Surgery and Bioengineering  
**PHS Funding:** NIH 1 R0 1HL117637-01 Paracorporeal Ambulatory Assist Lung  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** ALung Technologies, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh; consulting; reimbursed/sponsored travel; equity interest  
**Approximate dollar value of the SFI:** Consulting income and reimbursed/sponsored travel between $20,000 – $39,000; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

2. **Date Disclosed:** August 19, 2013  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 4 R37 HL058115-17 Redox Transduction of Nitric Oxide Signaling  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

3. **Date Disclosed:** August 19, 2013  
**Investigator with FCOI:** Francisco Schopfer, Ph.D.  
**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 4 R37 HL058115-17 Redox Transduction of Nitric Oxide Signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

4. Date Disclosed: July 31, 2014
Investigator with FCOI: Stephen H. Thorne, Ph.D.
Title: Assistant Professor of Cell Biology
PHS Funding: NIH 1 R01 CA178766-01A1 Creation of Immuno-Oncolytic Viruses for Cancer Therapy
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Western Oncolytics
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Western Oncolytics; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

5. FCOI eliminated February 24, 2016
Date Disclosed: February 4, 2015
Investigator with FCOI: Gregory Kato, M.D.
Title: Professor of Medicine
PHS Funding: NIH 1 R01 HL121386-01A1 Characterizing Mechanisms of Sickle Cell Crisis Via Dynamic Optical Assay
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Baxter
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $5,000 – $9,999

6. FCOI eliminated June 6, 2017
Date Disclosed: February 5, 2015
Investigator with FCOI: Marjorie Skubic, Ph.D., University of Missouri-Columbia
Title: Professor of Electrical and Computer Engineering
PHS Funding: AHRQ 1 R01 HS022889-01A1 Self-Management via Health Kiosk by Community-residing Older Adults
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Foresite Healthcare, LLC
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Missouri-Columbia and licensed to Foresite Healthcare, LLC; equity interest; advisor/board member

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

7.

**Date Disclosed:** February 17, 2015  
**Investigator with FCOI:** Lee M. Ritterband, Ph.D.  
**Title:** Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia  
**PHS Funding:** NIH 4 UH 3HL125103-01 *Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

8.

**Date Disclosed:** March 20, 2015  
**Investigator with FCOI:** Mark H. Yazer, M.D.  
**Title:** Professor of Pathology  
**PHS Funding:** NIH HHSN 268201100004 *Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Octapharma  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $5,000 – $9,999

9.

**Date Disclosed:** April 7, 2015  
**Investigator with FCOI:** Michael J. Palladino, PhD  
**Title:** Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1R01GM108073-01A1 *Pre-clinical Studies of Novel Mitochondrial Gene Therapies*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
10. **FCOI eliminated May 10, 2016**

**Date Disclosed:** April 15, 2015  
**Investigator with FCOI:** Michael J. Caterina, M.D., Ph.D.  
**Title:** Professor of Neurosurgery, Biological Chemistry and Neuroscience, Johns Hopkins University  
**PHS Funding:** NIH 5 R37DK054824-15 *Nitric Oxide in Bladder Neural-Epithelial Signaling*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Johns Hopkins University  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Johns Hopkins University and licensed to Merck  
**Approximate dollar value of the SFI:** $40,000 - $59,999

11. **FCOI eliminated December 29, 2015**

**Date Disclosed:** April 29, 2015  
**Investigator with FCOI:** Mary Rothstein  
**Title:** Research Specialist, University of Pittsburgh Cancer Institute  
**PHS Funding:** HHSN 261201400043C *Failed Tubulin Inhibitor Reformulated as Localized Adjuvant Therapy for Head and Neck Cancer*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Qrono, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Qrono, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

12.  

**Date Disclosed:** April 30, 2015  
**Investigator with FCOI:** Louis D. Falo, Jr., M.D., Ph.D.  
**Title:** Professor and Chair of Dermatology  
**PHS Funding:** 5 P50 CA121973-07 (Sub-project ID: 7388) *SPORE in Skin Cancer*  
**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** SkinJect  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

13.  

**Date Disclosed:** April 30, 2015  
**Investigator with FCOI:** Louis D. Falo, Jr., M.D., Ph.D.  
**Title:** Professor and Chair of Dermatology
PHS Funding: 5 R01 EB012776-04 Fabrication and Characterization of Dissolvable Microneedle Arrays
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

14. FCOI eliminated March 24, 2016

Date Disclosed: May 5, 2015
Investigator with FCOI: Chester Mathis, Ph.D.
Title: Professor of Radiology
PHS Funding: 3 U01 AG024904-10 Alzheimer’s Disease Neuroimaging Initiative
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare
Approximate dollar value of the SFI: $20,000 - $39,999

15.

Date Disclosed: May 14, 2015
Investigator with FCOI: Saul Shiffman, Ph.D.
Title: Professor of Psychology
PHS Funding: NIH 5 R01 DA034629-02 Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Reynolds American, Inc.; Niconovum (a subsidiary of Reynolds American, Inc.); JSR, LLC
Nature of the SFI: Consulting with Reynolds American and Niconovum; intellectual property rights (e.g., royalties, patents, copyrights) assigned to JSR; equity interest in JSR
Approximate dollar value of the SFI: Consulting income between $600,000 - $649,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

16. FCOI eliminated March 24, 2016

Date Disclosed: May 27, 2015
Investigator with FCOI: Chester Mathis, Ph.D.
Title: Professor of Radiology
PHS Funding: NIH 5 P50 AG005133-30 (Sub-Project ID: 6967) Natural History of Amyloid Deposition Familial Ad
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare
Approximate dollar value of the SFI: $20,000 - $39,999

17.
Date Disclosed: May 28, 2015
Investigator with FCOI: Steven Woodcock, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 AT006822 Formation of omega 3-derived electrophiles during inflammation
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

18.
Date Disclosed: May 28, 2015
Investigator with FCOI: Steven Woodcock, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

19.
Date Disclosed: May 28, 2015
Investigator with FCOI: Chen-Shan (Julia) Woodcock, M.S.
Title: Graduate Student Researcher, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

20.
Date Disclosed: May 28, 2015
Investigator with FCOI: Chen-Shan (Julia) Woodcock, M.S.
Title: Graduate Student Researcher, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 Redox-Derived Pulmonary Anti-Inflammatory Mediators
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

21.

Date Disclosed: May 28, 2015
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 Redox-Derived Pulmonary Anti-Inflammatory Mediators
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

22.

Date Disclosed: May 28, 2015
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 AT006822 Formation of omega 3-derived electrophiles during inflammation
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

23.

Date Disclosed: May 28, 2015
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

24. FCOI eliminated April 26, 2017

Date Disclosed: June 23, 2015
Investigator with FCOI: Brian Suffoletto, M.D.
Title: Assistant Professor of Emergency Medicine
PHS Funding: NIH 5 K23 AA023284-02 A Text-Message Intervention to Reduce Alcohol Use Among Young Adult ED Patients
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

25.

Date Disclosed: July 31, 2015
Investigator with FCOI: Brian Suffoletto, M.D.
Title: Assistant Professor of Emergency Medicine
PHS Funding: NIH R34 AA023047 Brief Alcohol Screening and Intervention for Community College Students (BASICCS)
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

26.

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 Redox-Derived Pulmonary Anti-Inflammatory Mediators
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

27.

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH P01 HL103455 Vascular Subphenotypes of Lung Disease
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999
28.  
Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH R01 AT006822 *Formation of omega 3-derived electrophiles during inflammation*  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

29.  
Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH R01 DK071085 *Roles of Nitric Oxide and Superoxide in Cystitis*  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

30.  
Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*  
Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

31.  
Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999
Date Disclosed: August 13, 2015
Investigator with FCOI: Francisco Schopfer, Ph.D.
Title: Research Associate Professor of Pharmacology and Chemical Biology
PHS Funding: NIH 1 R01 AR066548-01A1 The Immunoregulatory Effects of Electrophilic Fatty acids on Psoriasis
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: August 18, 2015
Investigator with FCOI: Mark Gladwin, M.D.
Title: Professor and Chair of Medicine
PHS Funding: NIH 1 K23 HL124051-01A1 Nitrite Modulation of Hypertension, Platelet Activation and Mitochondrial Function
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics
Approximate dollar value of the SFI: $1 - $4,999

FCOI eliminated March 24, 2016

Date Disclosed: October 1, 2015
Investigator with FCOI: Chester Mathis, Ph.D.
Title: Professor of Radiology
PHS Funding: NIH 1 K23 AG049945-01A1 The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older Adults
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare
Approximate dollar value of the SFI: $20,000 - $39,999
35. **FCOI eliminated March 24, 2016**

**Date Disclosed:** October 1, 2015  
**Investigator with FCOI:** William Klunk, M.D., Ph.D.  
**Title:** Professor of Psychiatry and Neurology  
**PHS Funding:** NIH 1 K23 AG049945-01A1 *The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older Adults*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare  
**Approximate dollar value of the SFI:** $20,000 - $39,999

36. **FCOI eliminated August 25, 2016**

**Date Disclosed:** February 3, 2016  
**Investigator with FCOI:** Fuchiang (Rich) Tsui, Ph.D.  
**Title:** Research Assistant Professor of Biomedical Informatics  
**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Vervtality  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

37. **FCOI eliminated April 26, 2017**

**Date Disclosed:** February 8, 2016  
**Investigator with FCOI:** James Eles  
**Title:** Graduate Student, Department of Bioengineering  
**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

38. **FCOI eliminated April 26, 2017**

**Date Disclosed:** February 8, 2016  
**Investigator with FCOI:** Xinyan (Tracy) Cui  
**Title:** Professor of Bioengineering  
**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*
Role on Research Project:  Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

39. **FCOI eliminated July 14, 2017**

Date Disclosed: February 12, 2016  
Investigator with FCOI: Edward Prochownik, M.D., Ph.D.  
Title: Professor of Pediatrics and Microbiology & Molecular Genetics  
PHS Funding: NIH 1 U54 CA199092-01 Center for Multiple Myeloma Nanotherapy  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

40.

Date Disclosed: February 22, 2016  
Investigator with FCOI: Andrew Hinck, Ph.D.  
Title: Visiting Professor of Structural Biology  
PHS Funding: NIH R01 CA172886 Inhibition of the Tumor-Promoting Effects of TGF-Beta in Advanced Prostate Cancer  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Texas Health Science Center at San Antonio  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Texas Health Science Center at San Antonio  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

41.

Date Disclosed: April 25, 2016  
Investigator with FCOI: Rebecca Jacobson, M.D., M.S.  
Title: Professor of Biomedical Informatics and Pathology  
PHS Funding: NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: NEXI
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

42.

**Date Disclosed:** April 25, 2016

**Investigator with FCOI:** Girish Chavan

**Title:** Staff, Department of Biomedical Informatics

**PHS Funding:** NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** NEXI

**Nature of the SFI:** Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

43.

**Date Disclosed:** April 25, 2016

**Investigator with FCOI:** Eugene Tseytlin

**Title:** Staff, Department of Biomedical Informatics

**PHS Funding:** NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** NEXI

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

44.

**Date Disclosed:** May 16, 2016

**Investigator with FCOI:** Dario Vitturi, Ph.D.

**Title:** Research Instructor, Department of Pharmacology & Chemical Biology

**PHS Funding:** NIH U01 HL117721 Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** $10,000 - $19,999
45.

Date Disclosed: June 9, 2016
Investigator with FCOI: Joseph Glorioso, Ph.D.
Title: Professor, Department of Microbiology & Molecular Genetics
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

46.

Date Disclosed: June 9, 2016
Investigator with FCOI: Paola Grandi, Ph.D.
Title: Assistant Professor, Department of Neurological Surgery
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

47.

Date Disclosed: June 9, 2016
Investigator with FCOI: Justus Cohen, Ph.D.
Title: Research Instructor, Department of Microbiology & Molecular Genetics
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
48.

Date Disclosed: June 9, 2016
Investigator with FCOI: William Goins, Ph.D.
Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

49.

Date Disclosed: June 9, 2016
Investigator with FCOI: Nduka Amankulor, M.D.
Title: Assistant Professor, Department of Neurological Surgery
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $5,000 - $9,999

50.

Date Disclosed: June 13, 2016
Investigator with FCOI: Paola Grandi, Ph.D.
Title: Assistant Professor, Department of Neurological Surgery
PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

51.

Date Disclosed: June 13, 2016
Investigator with FCOI: William Goins, Ph.D.
Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics
52.  
Date Disclosed: June 13, 2016  
Investigator with FCOI: Nduka Amankulor, M.D.  
Title: Assistant Professor, Department of Neurological Surgery  
PHS Funding: NIH R01 CA175052 Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus  
Nature of the SFI: Consulting; equity interest  
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

53.  
Date Disclosed: June 28, 2016  
Investigator with FCOI: Michael McClincy, M.D.  
Title: Fellow, Massachusetts General Hospital  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

54.  
Date Disclosed: June 28, 2016  
Investigator with FCOI: Kevin Bell, Ph.D.  
Title: Research Assistant Professor, Department of Orthopaedic Surgery  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

55. *FCOI eliminated August 25, 2016*

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** Robert Hartman, Ph.D.

**Title:** Postdoctoral Associate, Department of Physical Medicine & Rehabilitation

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

56.

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** Xinyan (Tracy) Cui

**Title:** Professor of Bioengineering

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

57. *FCOI eliminated September 2, 2016*

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** James Eles

**Title:** Graduate Student, Department of Bioengineering

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
58. **FCOI eliminated July 19, 2017**

**Date Disclosed:** July 1, 2016  
**Investigator with FCOI:** Joel S. Greenberger, M.D.  
**Title:** Professor and Chair of Radiation Oncology  
**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

59. **FCOI eliminated July 19, 2017**

**Date Disclosed:** July 1, 2016  
**Investigator with FCOI:** Michael W. Epperly, Ph.D.  
**Title:** Associate Professor of Radiation Oncology  
**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

60. **FCOI eliminated August 4, 2017**

**Date Disclosed:** July 5, 2016  
**Investigator with FCOI:** Shivalingappa Swamynathan, Ph.D.  
**Title:** Associate Professor of Ophthalmology and Cell Biology  
**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
61. **FCOI eliminated August 4, 2017**

**Date Disclosed:** July 5, 2016  
**Investigator with FCOI:** Sudha Swamynathan  
**Title:** Research Technician, Department of Ophthalmology  
**PHS Funding:** NIH R01 EY022898-03 *Corneal Expression and Function of Slurp1*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

62.

**Date Disclosed:** July 13, 2016  
**Investigator with FCOI:** Yuri Nikiforov, M.D., Ph.D.  
**Title:** Professor of Pathology  
**PHS Funding:** NIH 2 P50 CA097190-11 *Head and Neck Cancer SPORE*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to UPMC  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

63.

**Date Disclosed:** July 14, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
64.

Date Disclosed: July 14, 2016  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH 1 R21 AI122071-01A1 The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology  
Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

65.

Date Disclosed: August 9, 2016  
Investigator with FCOI: Dario A. Vignali, Ph.D.  
Title: Professor and Vice Chair of Immunology  
PHS Funding: NIH 9 R01 CA203689-07A1 Interleukin-35 and the Tumor Microenvironment  
Role on Research Project: Principal Investigator of bench, and Co-Investigator on non-bench, research  
Name of Entity in which Significant Financial Interest (SFI) is held: Tizona Therapeutics  
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children’s Research Hospital and licensed to Tizona Therapeutics;  
Approximate dollar value of the SFI: Consulting income between $80,000 - $99,999; licensing proceeds from intellectual property rights between $40,000 - $59,999; equity interest is SFI whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

66.

Date Disclosed: August 23, 2016  
Investigator with FCOI: Bruce Freeman, Ph.D.  
Title: Professor and Chair of Pharmacology and Chemical Biology  
PHS Funding: NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids  
Role on Research Project: Primary Mentor  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
67.  
**Date Disclosed:** August 23, 2016  
**Investigator with FCOI:** Dario Vitturi, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

68.  
**Date Disclosed:** August 23, 2016  
**Investigator with FCOI:** Francisco Schopfer, Ph.D.  
**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting; equity interest; Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.  
**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

69.  
**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Principal Investigator of animal, and Co-Investigator of bench and human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999
70. 

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

71. 

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Steven Woodcock, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

72. 

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Mark Gladwin, M.D.  
**Title:** Professor and Chair of Medicine  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** National Institutes of Health  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics  
**Approximate dollar value of the SFI:** $1 - $4,999

73. 

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology
PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: September 19, 2016
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: September 23, 2016
Investigator with FCOI: Steven Woodcock, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: September 23, 2016
Investigator with FCOI: Matthew Neal, M.D.
Title: Assistant Professor of Surgery and Critical Care Medicine

PHS Funding: NIH 1 R35 GM119526-01 Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After Trauma
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**77. FCOI eliminated March 29, 2017**

**Date Disclosed:** September 23, 2016  
**Investigator with FCOI:** Brian Suffoletto, M.D.  
**Title:** Assistant Professor of Emergency Medicine  
**PHS Funding:** NIH 1 R01 AA23650-01A1 *Mechanisms of Change for an Effective Alcohol Text Message Intervention*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**78.**

**Date Disclosed:** September 27, 2016  
**Investigator with FCOI:** Patricia Opresko, Ph.D.  
**Title:** Associate Professor of Environmental and Occupational Health  
**PHS Funding:** NIH 2 R44 GM108187-03 *GammaPNA Miniprobes for Telomere Analysis and RNA FISH*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to PNA Innovations, Inc.  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**79.**

**Date Disclosed:** October 5, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 U54 DK112079-01 *University of Pittsburgh O'Brien Cooperative Research Center Program*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999
Date Disclosed: October 10, 2016
Investigator with FCOI: Guergana Savova, Ph.D.
Title: Associate Professor of Pediatrics, Harvard Medical School and Computational Health Informatics Program at Boston Children’s Hospital
PHS Funding: NIH 5 U24 CA184407-03 Cancer Deep Phenotype Extraction from Electronic Medical Records
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Wired Informatics, LLC
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: October 18, 2016
Investigator with FCOI: John Kellum, M.D.
Title: Professor and Vice Chair for Research, Department of Critical Care Medicine
PHS Funding: NIH 1 R01 DK106256-01A1 Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Astute Medical
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: October 25, 2016
Investigator with FCOI: Alexander Deiters, Ph.D.
Title: Professor of Chemistry
PHS Funding: NIH 1 R21 HD 85206-01A1 Optical Control of Translation and Gene Editing in Zebrafish Embryos
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: North Carolina State University
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to North Carolina State University
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
83.

Date Disclosed: October 26, 2016  
Investigator with FCOI: Bonnie Hall, Ph.D.  
Title: Research Instructor, Department of Microbiology & Molecular Genetics  
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

84.

Date Disclosed: November 2, 2016  
Investigator with FCOI: Mary Loghmani, P.T., Ph.D.  
Title: Associate Professor of Physical Therapy, Indiana University  
PHS Funding: NIH 5 P2C HD086843-02 *Alliance for Regenerative Rehabilitation Research & Training (AR3T)*  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Health Smart Technologies, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

85.

Date Disclosed: November 17, 2016  
Investigator with FCOI: Maliha Zahid, M.D., Ph.D.  
Title: Research Instructor, Department of Developmental Biology  
PHS Funding: NIH 1 UL1 TR 001857-01 *University of Pittsburgh Clinical and Translational Science Institute*  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

86.

Date Disclosed: January 4, 2017  
Investigator with FCOI: Lee M. Ritterband, Ph.D.  
Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia
Feasibility and Acceptability of an internet-based cognitive-behavioral treatment for insomnia in adults with asthma

Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: January 17, 2017
Investigator with FCOI: Yadong Wang, Ph.D.
Title: Professor, Department of Bioengineering

Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair

Principal Investigator

Date Disclosed: March 2, 2017
Investigator with FCOI: Kenneth W. Kinzler, PhD
Title: Professor of Oncology, Johns Hopkins University

ctDNA for the Early Detection and Monitoring of Colorectal Cancer

Principal Investigator

Date Disclosed: June 21, 2017
Investigator with FCOI: Joseph Glorioso, PhD
Title: Professor of Microbiology & Molecular Genetics

Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector

Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between $100,000-$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: July 26, 2017
Investigator with FCOI: Beibei Bill Chen, PhD
Title: Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine
PHS Funding: NIH 5 UH3 HL123502 A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD
Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Koutif Therapeutics
Nature of the SFI: equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interests are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: July 26, 2017
Investigator with FCOI: Rama K. Mallampalli, MD
Title: Division Chief, Division of Pulmonary, Allergy, and Critical Care Medicine
PHS Funding: NIH 5 UH3 HL123502 A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD
Role on Research Project: Principal Investigator of bench, and Co-Investigator of animal, research
Name of the Entity in which Significant Financial Interest (SFI) is held: Koutif Therapeutics
Nature of the SFI: equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: July 26, 2017
Investigator with FCOI: Xiang-Qun (Sean) Xie, PhD, EMBA
Title: Associate Dean for Research Innovation and Professor, Department of Pharmaceutical Sciences
PHS Funding: NIH 1 R44 CA210882 SQSTM1/P62-Targeted Small Molecules for Multiple Myeloma Disease
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** ID4Pharma, LLC  
**Nature of the SFI:** equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned/licensed to ID4Pharma  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** August 9, 2017  
**Investigator with FCOI:** John M. Kirkwood, MD  
**Title:** Professor of Medicine, Division of Hematology/Oncology  
**PHS Funding:** NIH 5 U01 CA180820 *ECOG-ACRIN Operations Center*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Novartis  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

---

**Date Disclosed:** October 12, 2017  
**Investigator with FCOI:** Steven Moulton, MD  
**Title:** Professor of Surgery, University of Colorado School of Medicine  
**PHS Funding:** NIH 7 UM1 HL120877 *Analysis and Characterization of Trauma-Induced Coagulopathy*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Flashback Technologies, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Colorado and licensed to Flashback Technologies, Inc.; equity interest; consulting; management position  
**Approximate dollar value of the SFI:** Consulting income between $10,000-$19,999; intellectual property rights between $10,000-$19,999; management position is unpaid; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** November 8, 2017  
**Investigator with FCOI:** Francisco Schopfer, Ph.D.  
**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 5 R01 HL132550 *Anti-Inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting; equity interest
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

96.

Date Disclosed: November 15, 2017
Investigator with FCOI: Ling Wang, MD, PhD
Title: Research Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
PHS Funding: NIH 5 R01 HL125886 Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

97.

Date Disclosed: November 15, 2017
Investigator with FCOI: Charles F. McTiernan, PhD
Title: Research Associate Professor of Medicine, Division of Cardiology
PHS Funding: NIH 5 R01 HL125886 Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

98.

Date Disclosed: November 16, 2017
Investigator with FCOI: Jesus Tejero Bravo, PhD
Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
PHS Funding: NIH 5 R01 HL125886 Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.
Approximate dollar value of the SFI: Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
99.

**Date Disclosed:** November 16, 2017  
**Investigator with FCOI:** Jason J. Rose, MD, MBA  
**Title:** Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

100.

**Date Disclosed:** November 16, 2017  
**Investigator with FCOI:** Mark T. Gladwin, MD  
**Title:** Chair, Department of Medicine  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

101.

**Date Disclosed:** November 20, 2017  
**Investigator with FCOI:** Jesus Tejero Bravo, PhD  
**Title:** Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
**PHS Funding:** NIH 5 R21 ES027390 *Countermeasure Therapeutics for Acute Lung Injury*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.